Khorev N G, Kuznetsova D V
Department of Cardiology and Cardiovascular Surgery with a Course of Additional Professional Education, Barnaul, Russia.
Department of Pathological Anatomy, Altai State Medical University under the RF Ministry of Public Health, Barnaul, Russia.
Angiol Sosud Khir. 2021;27(1):84-89. doi: 10.33529/ANGIO2021110.
To evaluate the efficacy of a micronized purified flavonoid fraction in patients with primary venous disease. The study enrolled 31 patients, with varicose veins observed in a total of 47 lower extremities which were divided into 3 groups depending on the CEAP clinical class. The group of class C2 included 19 limbs, with the groups of C3 and C4 comprising 14 limbs each. The patients received a micronized purified flavonoid fraction (Detralex) in a daily dose of 1000 mg for 1 month. The venous function of the lower extremities was examined using venous photoplethysmography before and after the course of pharmacotherapy. Venous refilling time and venous half-refilling time were measured as indicators of total venous reflux. In the overall sample of patients with clinical class C2-C4, a significant increase in venous photoplethysmography parameters was found after the course of administration of the micronized purified flavonoid fraction. Thus, the venous refilling time increased from 15.5 (11; 19) s to 19.3 (13; 25) s, the venous half-refilling time increased from 6.5 (5; 7) s to 7.5 (5; 9) s. At the same time, in the group of patients with clinical class C2 and C3, a significant increase in the venous refilling time was found, and in patients with C4, the increase was not significant. There was an inverse correlation between the increase in venous refilling time after drug exposure and the clinical class of venous insufficiency according to the CEAP, as well as the patient's age. Thus, the administration of the micronized purified flavonoid fraction for 1 month in primary venous disease led to a decrease in the total venous reflux. The effect of the micronized purified flavonoid fraction on the total venous reflux was higher in younger patients and in patients with a lower clinical class of the disease.
评估微粉化纯化黄酮类成分对原发性静脉疾病患者的疗效。该研究纳入了31例患者，共47条下肢存在静脉曲张，根据CEAP临床分级分为3组。C2级组包括19条肢体，C3级和C4级组各包括14条肢体。患者接受每日剂量为1000 mg的微粉化纯化黄酮类成分（地奥司明），持续1个月。在药物治疗疗程前后，使用静脉光电容积描记法检查下肢的静脉功能。测量静脉充盈时间和静脉半充盈时间作为总静脉反流的指标。在C2 - C4级临床分级的患者总体样本中，发现给予微粉化纯化黄酮类成分疗程后，静脉光电容积描记法参数有显著增加。因此，静脉充盈时间从15.5（11；19）秒增加到19.3（13；25）秒，静脉半充盈时间从6.5（5；7）秒增加到7.5（5；9）秒。同时，在C2级和C3级临床分级的患者组中，发现静脉充盈时间有显著增加，而在C4级患者中，增加不显著。药物暴露后静脉充盈时间的增加与根据CEAP分级的静脉功能不全临床分级以及患者年龄呈负相关。因此，在原发性静脉疾病中给予微粉化纯化黄酮类成分1个月可导致总静脉反流减少。微粉化纯化黄酮类成分对总静脉反流的作用在年轻患者和疾病临床分级较低的患者中更高。
